Skip to main content
NVDA-2.30%AAPL+3.37%GOOGL+0.60%MSFT+0.16%AMZN-0.27%TSM-1.46%SPCX+0.04%AVGO-1.03%META-1.45%TSLA-1.26%SKHY-5.17%MU-4.80%BRK-B+0.11%LLY-0.01%JPM-0.41%WMT-0.07%AMD-3.27%V+0.04%XOM+0.72%ASMLa-1.66%JNJ-0.31%INTC-5.37%MA-0.31%0700.HK-1.94%1398.HK+0.79%ORCL-4.76%ABBV+1.45%BAC-0.17%CSCO-1.64%CVX-0.43%COST+0.03%KO+0.51%LRCX-5.73%CAT-1.43%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.08%HSBA.L-1.30%DELL-4.76%PG+0.25%MS-1.03%GE-0.45%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.15%HD-1.70%0939.HK+1.66%GS-1.06%NZDJPY-2.62%AUDJPY-1.86%CHFJPY-1.61%NZDCAD-1.45%EURNZD+1.42%NZDUSD-1.41%GBPNZD+1.36%GBPJPY-1.27%EURJPY-1.25%USDJPY-1.24%CADJPY-1.19%NZDCHF-1.05%USDZAR+1.02%USDSEK+0.93%USDNOK+0.90%EURZAR+0.84%AUDNZD+0.79%GBPZAR+0.75%EURSEK+0.74%EURNOK+0.72%AUDCAD-0.70%USDTHB+0.70%AUDDKK-0.65%AUDUSD-0.63%EURAUD+0.62%CHFSEK+0.59%USDMXN+0.58%GBPAUD+0.57%CHFNOK+0.57%AUDSGD-0.55%USDPLN+0.44%GBPTRY+0.41%CADCHF+0.41%NZDSGD-0.40%NOKJPY-0.40%USDCHF+0.39%EURCHF+0.36%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.28%EURPLN+0.26%AUDCHF-0.25%SGDJPY+0.22%EURHKD-0.19%USDDKK+0.18%USDILS+0.16%NZDMXN-0.12%USDTRY+0.11%USDCNH+0.10%EURSGD+0.10%GBPCAD-0.10%AUDNOK+0.07%EURCNH-0.06%EURCAD-0.06%PLNJPY+0.06%EURCZK-0.06%CHFSGD-0.05%EURGBP+0.04%USDCOP-0.04%USDCAD-0.04%GBPUSD-0.03%USDHKD+0.02%EURUSD-0.02%GBPSGD+0.01%EURDKK0.00%XPTUSD-6.24%UKOIL+5.70%USOIL+5.46%GAGUSD-5.34%XAGUSD-5.34%HG1-4.81%XAUUSD-1.76%GAUUSD-1.76%XNGUSD+1.51%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.51%ETHUSD-0.25%USDTUSD-0.02%XRPUSD-3.14%SOLUSD-1.78%TRXUSDT+0.18%ZECUSDT-9.66%DOGEUSD-2.61%XMRUSDT+0.15%LINKUSD-1.60%XLMUSD-1.85%BCHUSDT-9.95%LTCUSD-1.86%UNIUSD-1.29%TONUSD+24.88%HBARUSDT-2.36%SUIUSD-4.33%TAOUSDT-5.94%AAVEUSD-2.15%DOTUSDT-2.01%ICPUSDT-0.94%ONDOUSDT-3.59%WLDUSDT-3.39%ATOMUSDT-3.57%ARBUSDT-1.23%JUPUSDT-4.25%INJUSDT-3.17%STXUSDT-4.53%FETUSDT-3.21%TIAUSDT-1.65%PYTHUSDT-1.77%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-5.38%GRTUSDT-4.03%OPUSDT-4.00%POLUSDT-4.61%IOTAUSDT-4.39%AXSUSDT-2.47%FARTCOINUSDT-3.46%EOSUSDT-2.91%DYDXUSDT-2.53%ORDIUSDT-1.30%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.30%AAPL+3.37%GOOGL+0.60%MSFT+0.16%AMZN-0.27%TSM-1.46%SPCX+0.04%AVGO-1.03%META-1.45%TSLA-1.26%SKHY-5.17%MU-4.80%BRK-B+0.11%LLY-0.01%JPM-0.41%WMT-0.07%AMD-3.27%V+0.04%XOM+0.72%ASMLa-1.66%JNJ-0.31%INTC-5.37%MA-0.31%0700.HK-1.94%1398.HK+0.79%ORCL-4.76%ABBV+1.45%BAC-0.17%CSCO-1.64%CVX-0.43%COST+0.03%KO+0.51%LRCX-5.73%CAT-1.43%AP2d-1.55%0005.HK-0.78%AMAT-3.17%UNH-1.08%HSBA.L-1.30%DELL-4.76%PG+0.25%MS-1.03%GE-0.45%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.15%HD-1.70%0939.HK+1.66%GS-1.06%NZDJPY-2.62%AUDJPY-1.86%CHFJPY-1.61%NZDCAD-1.45%EURNZD+1.42%NZDUSD-1.41%GBPNZD+1.36%GBPJPY-1.27%EURJPY-1.25%USDJPY-1.24%CADJPY-1.19%NZDCHF-1.05%USDZAR+1.02%USDSEK+0.93%USDNOK+0.90%EURZAR+0.84%AUDNZD+0.79%GBPZAR+0.75%EURSEK+0.74%EURNOK+0.72%AUDCAD-0.70%USDTHB+0.70%AUDDKK-0.65%AUDUSD-0.63%EURAUD+0.62%CHFSEK+0.59%USDMXN+0.58%GBPAUD+0.57%CHFNOK+0.57%AUDSGD-0.55%USDPLN+0.44%GBPTRY+0.41%CADCHF+0.41%NZDSGD-0.40%NOKJPY-0.40%USDCHF+0.39%EURCHF+0.36%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%USDSGD+0.28%EURPLN+0.26%AUDCHF-0.25%SGDJPY+0.22%EURHKD-0.19%USDDKK+0.18%USDILS+0.16%NZDMXN-0.12%USDTRY+0.11%USDCNH+0.10%EURSGD+0.10%GBPCAD-0.10%AUDNOK+0.07%EURCNH-0.06%EURCAD-0.06%PLNJPY+0.06%EURCZK-0.06%CHFSGD-0.05%EURGBP+0.04%USDCOP-0.04%USDCAD-0.04%GBPUSD-0.03%USDHKD+0.02%EURUSD-0.02%GBPSGD+0.01%EURDKK0.00%XPTUSD-6.24%UKOIL+5.70%USOIL+5.46%GAGUSD-5.34%XAGUSD-5.34%HG1-4.81%XAUUSD-1.76%GAUUSD-1.76%XNGUSD+1.51%SUGAR0.00%S10.00%COFFEE0.00%BTCUSD-1.51%ETHUSD-0.25%USDTUSD-0.02%XRPUSD-3.14%SOLUSD-1.78%TRXUSDT+0.18%ZECUSDT-9.66%DOGEUSD-2.61%XMRUSDT+0.15%LINKUSD-1.60%XLMUSD-1.85%BCHUSDT-9.95%LTCUSD-1.86%UNIUSD-1.29%TONUSD+24.88%HBARUSDT-2.36%SUIUSD-4.33%TAOUSDT-5.94%AAVEUSD-2.15%DOTUSDT-2.01%ICPUSDT-0.94%ONDOUSDT-3.59%WLDUSDT-3.39%ATOMUSDT-3.57%ARBUSDT-1.23%JUPUSDT-4.25%INJUSDT-3.17%STXUSDT-4.53%FETUSDT-3.21%TIAUSDT-1.65%PYTHUSDT-1.77%SEIUSDT-6.02%IMXUSDT-3.85%WIFUSDT-5.38%GRTUSDT-4.03%OPUSDT-4.00%POLUSDT-4.61%IOTAUSDT-4.39%AXSUSDT-2.47%FARTCOINUSDT-3.46%EOSUSDT-2.91%DYDXUSDT-2.53%ORDIUSDT-1.30%GALAUSDT-3.65%NOTUSDT-2.97%RONINUSDT-2.64%
CT

Cullinan Therapeutics, Inc. (CGEM)

NASDAQ • Healthcare

$21.31
-$0.38 (-1.8%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$21.3
Previous Close$21.31
Day Range$21.08 - $21.8
Avg. Volume (3M)757.1K
Market Cap$1.2B
52 Week Range
$5.68$23.19
Next EarningsIn 56 daysNov 5, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$204.6M
EPS (TTM)
-$3.37
ROA (TTM)
-56.27%
Current Ratio
8.42

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+3.8%Q1 2026-$0.77
+10.3%Q2 2026-$0.75
-1.3%Q3 2026-$0.81
Next

Nov 5

in 56 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -1.3%

Cullinan Therapeutics’ loss per share was slightly wider than consensus, with preliminary results for the second fiscal quarter of 2026 reported August 6, 2026 showing EPS of -$0.81 trailed the -$0.80 estimate by -$0.01, while the company continued to operate as a clinical-stage oncology developer across programs such as CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. Net income improved ~23% year over year to about -$53.7 million (up from -$70.1 million a year ago), alongside a ~24% year-over-year improvement in EPS from -$1.07. Operating income for the quarter was about -$57.3 million, and the company generated negative operating cash flow of roughly -$38.2 million, reflecting ongoing spend to advance its pipeline rather than support a marketed product base. For the next period, consensus calls for EPS of -$0.85 on revenue of $2.0 million.

View full earnings history

About Cullinan Therapeutics, Inc.

Cullinan Therapeutics, Inc. is a NASDAQ-listed biotechnology company focused on developing cancer treatments that draw on the immune system. Trading as CGEM, it operates as a clinical-stage drug developer in healthcare, advancing a pipeline of oncology candidates rather than a marketed product portfolio.

Name
Cullinan Therapeutics, Inc.
CEO
Nadim Ahmed
Website
cullinantherapeutics.com
Industry
Healthcare
Year Founded
2016
Employees
109

Today's Snapshot

AI-generated

CGEM is trading 1.8% below yesterday's close, in line with a weaker sector. Cullinan Therapeutics announced an investor event to present interim Phase 3 results for its lung-cancer drug zipalertinib.

Trading Volume

Below 10d avg (692.7K)

508.8K

vs S&P 500 Today

Underperforming Market

-1.17%

Updated: September 10, 2026 at 19:04 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
CGEM carries a buy tilt driven by a firming trend and constructive medium- to long-term moving averages, while the short-term averages sit slightly above the market, producing a near-term pullback within a broader uptrend. Momentum is mixed with a modest MACD positive reading and a neutral RSI, and the ADX suggests a developing trend rather than a weak one. Volume metrics are soft despite the rising longer-term averages, and volatility is moderate, keeping moves contained. The classic pivot is near current levels and provides a nearby reference. Technical takeaway: Buy.
All signals
  • EMA (5 indicators)$14.87 - $21.64
    Buy
  • RSI (14)51.25
    Neutral
  • Stochastic %K (14, 3, 3)20.50
    Neutral
  • MACD Level (12, 26)0.73
    Neutral

Peers & Related Assets

OMEROmeros Corporation
$19.39+1.4%
CBLLCeriBell, Inc.
$24.41+0.4%
VREXVarex Imaging Corporation
$18.5+0.1%
LABStandard BioTools Inc.
$0.73+5.1%
ADCTADC Therapeutics S.A.
$1.22-6.2%
RAPTRAPT Therapeutics, Inc.
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.